新辅助放化疗对食管癌术后ki-67、CD44v6及PD-1/PD-L1表达的影响

doi:10.3969/j.issn.1671-7171.2023.12.020

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1280 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To explore the effects of neoadjuvant radiotherapy and chemotherapy on the expression of nuclear protein (ki-67), integrated membrane glycoprotein (CD44v6), and programmed cell death protein-1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) in postoperative esophageal cancer patients. 【Method】A total of 76 patients with esophageal cancer were randomly divided into an observation group and a control group, with 38 cases in each group. Both groups of patients underwent routine esophageal cancer radical surgery, while the observation group received neoadjuvant chemotherapy before surgery. We compared perioperative indicators, clinical efficacy, postoperative ki-67, CD44v6, PD-1/PD-L1 expression levels, and incidence of complications between two groups of patients. 【Results】There was no statistically significant difference in intraoperative bleeding, surgical time, and pleural fluid volume between the two groups of patients (P>0.05); The length of hospital stay in the observation group was less than that in the control group (P<0.05). The objective effective rate of the observation group patients was 76.32% (29/38), significantly higher than the control group's 52.63% (20/38) (P<0.05). The positive expression rate of ki-67 protein and the levels of CD44v6 and PD-1/PD-L1 in the observation group were lower than those in the control group after surgery (P<0.05). There was no statistically significant difference in the total incidence of complications between the two groups of patients (P>0.05). 【Conclusion】Preoperative neoadjuvant radiotherapy and chemotherapy can effectively improve the clinical efficacy and immune function of esophageal cancer patients, with high safety.

Key words： Esophageal Neoplasms/SU Esophageal Neoplasms/RT Esophageal Neoplasms/DT Ki-67 Antigen Hyaluronan Receptors

Received: 26 July 2022

PACS:

R735.1

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	GONG Xiangping
	SHI Yongtie

Cite this article:

GONG Xiangping,SHI Yongtie. The Effect of Neoadjuvant Radiotherapy and Chemotherapy on the Expression of ki-67, CD44v6, and PD-1/PD-L1 after Esophageal Cancer Surgery[J]. JOURNAL OF CLINICAL RESEARCH, 2023, 40(12): 1892-1894.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2023.12.020 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2023/V40/I12/1892

[1] 赫捷,邵康. 中国食管癌流行病学现状、诊疗现状及担任中华未来对策[J].中国癌症杂志,2011,21(7):501-504.
[2] SMITHERS B M,THOMSON I. Neoadjuvant chemotherapy or chemoradiotherapy for locally advanced esophageal cancer[J].Thorac Surg Clin,2013, 23(4):509-523.
[3] 律方,薛奇,邵康,等.国际抗癌联盟-美国癌症联合委员会食管癌分期第7版临床应用的初步体会[J].中华肿瘤杂志,2012,34(6):461-464.
[4] EISENHAUER E A,THERASSE P,BOGAERTS J,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J].Eur J Cancer,2009, 45(2):228-247.
[5] MAKOTO Y,HIROSHI M,YASUHIRO M,et al.Perioperative therapy for esophageal cancer[J].Gen Thorac Cardiovasc Surg,2014,62(9):531-540.
[6] VALLBHMER D,HLSCHER A H,DEMEESTER S,et al. A multicenter study of survival after neoadjuvant radiotherapy/chemotherapy and esophagectomy for ypT0N0M0R0 esophageal cancer[J].Ann Surg,2010, 252(5):744-749.
[7] ZHANG X,WATSON D I,JAMIESON G G,et al. Neoadjuvant chemoradiotherapy for esophageal carcinoma[J].Dis Esophagus,2010, 18(2):104-108.
[8] 岳泓旭,徐新建,李飞,等. 新辅助放化疗联合手术治疗老年晚期食管癌患者的安全性及远期疗效分析[J].实用癌症杂志,2016,31(4):595-597.
[9] 杨丽萍,王烈亮,梁璟慧,等.新辅助化疗对乳腺癌患者远、近期疗效及Ki-67表达的影响[J].中国老年学杂志,2016,36(22):5620-5621.
[10] 赵松,付明倜,胡伟,等. 食管癌患者血清中SCD44V6及组织中CD44V6表达的临床意义[J].中华医学杂志,2003,83(21):1919-1920.
[11] 王耿杰,马良赟,沈宇舟,等. PD-1、PD-L1表达与食管癌的临床病理特征及预后的关系[J].中国实验诊断学,2018,22(10):1751-1753.
[12] 务森,陈明耀,雒建超,等.高龄局部进展期食管癌患者术前新辅助放化疗的安全性和疗效观察[J].肿瘤防治研究,2012,39(7):838-840.